SuperworthVyome free cash flow HIND
Cash from operations less capital spending, by quarter and over the last twelve months, from 2015.
- Last 12 months, to Dec 31, 2023
- −$17M
- Latest quarter, Q4 FY23
- −$2.5M
- Fiscal year 2023
- −$17M
Vyome's free cash flow was −$17M over the twelve months to Dec 31, 2023.
In its latest quarter, Q4 FY23, it was −$2.5M.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2023 | −$17M | n/a |
| FY2022 | −$22M | n/a |
| FY2021 | −$15.7M | n/a |
| FY2020 | −$10.7M | n/a |
| FY2019 | −$23.1M | n/a |
| FY2018 | −$30.7M | n/a |
| FY2017 | −$31.7M | n/a |
| FY2016 | −$19.7M | n/a |
| FY2015 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY23 | −$2.5M | n/a | −$17M | |
| Q3 FY23 | −$2.8M | n/a | −$17.5M | |
| Q2 FY23 | −$6.7M | n/a | −$20M | |
| Q1 FY23 | −$5.1M | n/a | −$19.7M | |
| Q4 FY22 | −$2.9M | n/a | −$22M | |
| Q3 FY22 | −$5.3M | n/a | −$22.6M | |
| Q2 FY22 | −$6.4M | n/a | −$25.2M | |
| Q1 FY22 | −$7.4M | n/a | −$21M | |
| Q4 FY21 | −$3.5M | n/a | −$15.7M | |
| Q3 FY21 | −$7.9M | n/a | −$14.2M | |
| Q2 FY21 | −$2.3M | n/a | −$7.4M | |
| Q1 FY21 | −$2.1M | n/a | −$7.6M |
Against its peers
Companies in Drug Manufacturers - General nearest Vyome's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| HINDVyome | n/m |
| ATNMActinium Pharmaceuticals | n/m |
| SPROSpero Therapeutics | n/m |
| LFVNLifevantage | 9.1% |
| Peer median | 9.1% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Vyome
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.